139503 20240529141902.0 10.1016/j.neuroimage.2017.05.058 doi pmid:28587897 pmid pmc:PMC5814575 pmc 1053-8119 ISSN 1095-9572 ISSN altmetric:20803968 altmetric DZNE-2020-05825 English 610 Maaß, Anne P:(DE-2719)2811815 0 First author dzne Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease. Orlando, Fla. 2017 Academic Press print Crossref Elsevier BV 2017-08-01 article DRIVER Output Types/Journal article DataCite Journal Article journal journal PUB:(DE-HGF)16 1715349548_4830 PUB:(DE-HGF) ARTICLE BibTeX JOURNAL_ARTICLE ORCID Journal Article 0 EndNote The recent development of tau-specific positron emission tomography (PET) tracers enables in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease (AD). Tau PET imaging may become a useful biomarker for clinical diagnosis and tracking of disease progression but there is no consensus yet on how tau PET signal is best quantified. The goal of the current study was to evaluate multiple whole-brain and region-specific approaches to detect clinically relevant tau PET signal. Two independent cohorts of cognitively normal adults and amyloid-positive (Aβ+) patients with mild cognitive impairment (MCI) or AD-dementia underwent [18F]AV-1451 PET. Methods for tau tracer quantification included: (i) in vivo Braak staging, (ii) regional uptake in Braak composite regions, (iii) several whole-brain measures of tracer uptake, (iv) regional uptake in AD-vulnerable voxels, and (v) uptake in a priori defined regions. Receiver operating curves characterized accuracy in distinguishing Aβ- controls from AD/MCI patients and yielded tau positivity cutoffs. Clinical relevance of tau PET measures was assessed by regressions against cognition and MR imaging measures. Key tracer uptake patterns were identified by a factor analysis and voxel-wise contrasts. Braak staging, global and region-specific tau measures yielded similar diagnostic accuracies, which differed between cohorts. While all tau measures were related to amyloid and global cognition, memory and hippocampal/entorhinal volume/thickness were associated with regional tracer retention in the medial temporal lobe. Key regions of tau accumulation included medial temporal and inferior/middle temporal regions, retrosplenial cortex, and banks of the superior temporal sulcus. Our data indicate that whole-brain tau PET measures might be adequate biomarkers to detect AD-related tau pathology. However, regional measures covering AD-vulnerable regions may increase sensitivity to early tau PET signal, atrophy and memory decline. 344 - Clinical and Health Care Research (POF3-344) G:(DE-HGF)POF3-344 POF3-344 POF III 0 2017-08-01 Crossref https://www.elsevier.com/tdm/userlicense/1.0/ 2018-06-21 Crossref http://www.elsevier.com/open-access/userlicense/1.0/ Dataset connected to CrossRef, PubMed, Amyloid beta-Peptides NLM Chemicals Carbolines NLM Chemicals tau Proteins NLM Chemicals 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole J09QS3Z3WB NLM Chemicals Adult MeSH Age of Onset MeSH Aged MeSH Aged, 80 and over MeSH Aging: metabolism MeSH Alzheimer Disease: diagnostic imaging MeSH Alzheimer Disease: metabolism MeSH Alzheimer Disease: pathology MeSH Alzheimer Disease: physiopathology MeSH Amyloid beta-Peptides: metabolism MeSH Carbolines MeSH Cognitive Dysfunction: diagnostic imaging MeSH Cognitive Dysfunction: metabolism MeSH Cognitive Dysfunction: pathology MeSH Cognitive Dysfunction: physiopathology MeSH Cohort Studies MeSH Female MeSH Humans MeSH Male MeSH Middle Aged MeSH Neocortex: diagnostic imaging MeSH Neocortex: metabolism MeSH Positron-Emission Tomography: methods MeSH Severity of Illness Index MeSH Young Adult MeSH tau Proteins: metabolism MeSH Landau, Susan 1 Baker, Suzanne L 2 Horng, Andy 3 Lockhart, Samuel N 4 La Joie, Renaud 5 Rabinovici, Gil D 6 Jagust, William J 7 Initiative, Alzheimer's Disease Neuroimaging 8 10.1016/j.neuroimage.2017.05.058 : Elsevier BV, 2017-08-01 448-463 journal-article Crossref NeuroImage 157 2017 1053-8119 10.1016/j.neuroimage.2017.05.058 Vol. 157, p. 448 - 463 PERI:(DE-600)1471418-8 157<448 - 463 448-463 NeuroImage 157 2017 1053-8119 Pubmed Central http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814575 http://pub.dzne.de/record/139503/files/DZNE-2020-05825_Restricted.pdf http://pub.dzne.de/record/139503/files/DZNE-2020-05825_Restricted.pdf?subformat=pdfa pdfa VDB oai:pub.dzne.de:139503 Deutsches Zentrum für Neurodegenerative Erkrankungen I:(DE-588)1065079516 DZNE 0 P:(DE-2719)2811815 DE-HGF Gesundheit Erkrankungen des Nervensystems G:(DE-HGF)POF3-340 G:(DE-HGF)POF3-344 G:(DE-HGF)POF3 G:(DE-HGF)POF3-300 G:(DE-HGF)POF Clinical and Health Care Research 0 2017 Nationallizenz StatID:(DE-HGF)0420 StatID 2022-11-12 ger JCR StatID:(DE-HGF)0100 StatID NEUROIMAGE : 2021 2022-11-12 DBCoverage StatID:(DE-HGF)0200 StatID SCOPUS 2022-11-12 DBCoverage StatID:(DE-HGF)0300 StatID Medline 2022-11-12 DBCoverage StatID:(DE-HGF)0501 StatID DOAJ Seal 2022-09-27T20:29:23Z Peer Review StatID:(DE-HGF)0030 StatID DOAJ : Blind peer review 2022-09-27T20:29:23Z DBCoverage StatID:(DE-HGF)0600 StatID Ebsco Academic Search 2022-11-12 Peer Review StatID:(DE-HGF)0030 StatID ASC 2022-11-12 DBCoverage StatID:(DE-HGF)0199 StatID Clarivate Analytics Master Journal List 2022-11-12 DBCoverage StatID:(DE-HGF)0150 StatID Web of Science Core Collection 2022-11-12 DBCoverage StatID:(DE-HGF)1050 StatID BIOSIS Previews 2022-11-12 DBCoverage StatID:(DE-HGF)1030 StatID Current Contents - Life Sciences 2022-11-12 IF >= 5 StatID:(DE-HGF)9905 StatID NEUROIMAGE : 2021 2022-11-12 I:(DE-2719)5000006 AG Düzel Clinical Neurophysiology and Memory 0 journal VDB I:(DE-2719)5000006 UNRESTRICTED